HAVLF Company Profile and Key Details

Q: Who are the executives of HAVLF?

Ms. Jenna PozarChief Operations OfficerMr. Paul MoreControllerMr. Tim MooreInterim Chief Financial Officer, Chief Executive Officer & Chairman

PNK : HAVLF

HAVN Life Sciences

$0.01

0.0001+1.00%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

HAVN Life Sciences Inc. (HAVLF) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.01 during the session.

Stock Snapshot

0.0001

Prev. Close

2.57K

Market Cap

0.0001

Day Low

N/A

P/E Ratio

-23.28874

EPS (TTM)

0.03

Cash Flow per Share

Open

25.65M

Number of Shares

0.01

Day High

90.06%

Free Float in %

N/A

Book Value

22.11K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 27, 2026	0.00	0.00	0.00	0.00	700
Dec 29, 2025	0.00	0.00	0.00	0.00	338
Dec 24, 2025	0.00	0.00	0.00	0.00	666
Dec 22, 2025	0.00	0.00	0.00	0.00	163
Dec 12, 2025	0.00	0.00	0.00	0.00	166
Dec 10, 2025	0.00	0.00	0.00	0.00	207
Dec 08, 2025	0.00	0.00	0.00	0.00	1.97K
Nov 24, 2025	0.00	0.00	0.00	0.00	232
Nov 05, 2025	0.00	0.00	0.00	0.00	11.99K
Oct 29, 2025	0.00	0.00	0.00	0.00	166
Sep 26, 2025	0.00	0.00	0.00	0.00	303
Sep 18, 2025	0.00	0.00	0.00	0.00	0
Sep 15, 2025	0.00	0.00	0.00	0.00	0
Sep 11, 2025	0.00	0.00	0.00	0.00	0
Sep 08, 2025	0.00	0.00	0.00	0.00	0
Sep 04, 2025	0.00	0.00	0.00	0.00	0
Sep 02, 2025	0.00	0.00	0.00	0.00	22.11K
Aug 26, 2025	0.00	0.00	0.00	0.00	0
Aug 22, 2025	0.00	0.00	0.00	0.00	22.11K
Aug 15, 2025	0.00	0.00	0.00	0.00	2.58K

Contact Details

Port Moody, BC V3H 0E3

Canada

https://www.havnlife.com 604 687 7130

About Company

HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health products utilizing unregulated ingredients. Founded in 2020, HAVN Life Sciences' operations are headquartered in Richmond, Canada.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00

Company Overview

The stock is currently mid-range between its 52-week high and low $0.00 and $0.01. With a market capitalization of about $2.56 thousand, HAVN Life Sciences Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.30). Key stats such as the average daily volume over the past year has been around 20.19 thousand shares, in line with its 52-week average. Headquartered in Port Moody, BC, HAVN Life Sciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tim Moore, the company employs approximately 6 people and listed since January 08, 2021. HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms.

Valuation Metrics

HAVN Life Sciences Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.01 The P/FCF stands at -0.0, also above market averages.

Dividend & Fair Value

HAVN Life Sciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.10. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, HAVN Life Sciences has not generated any revenue.
On valuation metrics, HAVN Life Sciences trades at a P/E of -0.00, P/S of 0.01 and P/B of 0.00. The current ratio is 4.51 and quick ratio is 2.62. Operationally, the company’s inventory turnover is 0.16 and cash conversion cycle is 1816.96 days. Debt-to-equity is 0.12, supported by a cash flow-to-debt ratio of -20.23.

Quarterly Financial Highlights

For the quarter ended Apr 30, 2023, HAVN Life Sciences posted revenue of $0.00, down slightly from $276.47K in the prior quarter.

Price Forecast & Outlook

Our AI price prediction model suggests that HAVN Life Sciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows HAVN Life Sciences Inc. trading at a premium to the broader market with a P/E of -0.0.

Frequently Asked Questions

What is the current HAVN Life Sciences Inc. (HAVLF) stock price?

HAVN Life Sciences Inc. (OTC: HAVLF) stock price is $0.00 in the last trading session. During the trading session, HAVLF stock reached the peak price of $0.01 while $0.00 was the lowest point it dropped to. The percentage change in HAVLF stock occurred in the recent session was 0% while the dollar amount for the price change in HAVLF stock was $0.00.

HAVLF's industry and sector of operation?

The OTC listed HAVLF is part of Biotechnology industry that operates in the broader Healthcare sector. HAVN Life Sciences Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HAVLF?

Ms. Jenna Pozar
Chief Operations Officer
Mr. Paul More
Controller
Mr. Tim Moore
Interim Chief Financial Officer, Chief Executive Officer & Chairman

How HAVLF did perform over past 52-week?

HAVLF's closing price is 68.33% higher than its 52-week low of $0.00 where as its distance from 52-week high of $0.01 is -93.27%.

How many employees does HAVLF have?

Number of HAVLF employees currently stands at 6.

Link for HAVLF official website?

Official Website of HAVLF is: https://www.havnlife.com

How do I contact HAVLF?

HAVLF could be contacted at phone 604 687 7130 and can also be accessed through its website. HAVLF operates from 605 - 130 Brew Street, Port Moody, BC V3H 0E3, Canada.

How many shares of HAVLF are traded daily?

HAVLF stock volume for the day was 22.11K shares. The average number of HAVLF shares traded daily for last 3 months was 20.19K.

What is the market cap of HAVLF currently?

The market value of HAVLF currently stands at $2.57K with its latest stock price at $0.00 and 25.65M of its shares outstanding.

Employees	6
Beta	-0.3
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	April
Sector	Healthcare
Industry	Biotechnology

HAVLF Company Profile and Key Details

HAVN Life Sciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics